In patients with solid tumours, including a subset of patients with breast and ovarian cancers, treated at a dose of 50 mg/ m2/ cycle with lifetime cumulative anthracycline doses up to 1,532 mg/ m2, the incidence of clinically significant cardiac dysfunction was low.